Weight Loss in Adults Using Semaglutide (Real-world Study)

Recruiting now

Conditions studied: Overweight, Obesity

In brief

The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.

Key facts

Study ID

NCT07627074

Run by

Novo Nordisk A/S

People needed

35000

Starts

2026-05-12

Expected to finish

2026-06-01

Last updated by the study team

2026-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Initiation of semaglutide for weight management during the study period.
• Age more than or equal to (≥) 18 at treatment initiation
• Baseline body mass index (BMI) ≥27 and less than (<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2.
• Other inclusion criteria as defined in the protocol are applicable.

You may not qualify if…

• Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
• Bariatric surgery at baseline.
• Diabetes at baseline.
• Pregnancy at baseline.

Where it is running

• Novo Nordisk Investigational Site — Seattle, Washington, United States (enrolling)
• Novo Nordisk Investigational Site — London, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.